STOCK TITAN
  1. Home
  2. News
  3. UCBJY

UCB SA - UCBJY STOCK NEWS

IMPACT
SENTIMENT
UCBJY : OTC
BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis
IMPACT
SENTIMENT
UCBJY : OTC
UCB announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the treatment of adults with generalized myasthenia gravis
fda approval
IMPACT
SENTIMENT
UCBJY : OTC
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023
IMPACT
SENTIMENT
UCBJY : OTC
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa
clinical trial
IMPACT
SENTIMENT
UCBJY : OTC
UCB presents late-breaking posters at Child Neurology Society Meeting
IMPACT
SENTIMENT
UCBJY : OTC
UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
IMPACT
SENTIMENT
UCBJY : OTC
UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis
fda approval
IMPACT
SENTIMENT
UCBJY : OTC
UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting
IMPACT
SENTIMENT
UCBJY : OTC
UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance
IMPACT
SENTIMENT
UCBJY : OTC
Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks
clinical trial
Stock UCBJY logo
UCB SA
OTC:UCBJY

UCBJY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link